LLY Eli Lilly and Company
USHealthcareAs of 2026-10-08
Why LLY matters now
Eli Lilly and Company (LLY) is a US stock in Healthcare. The latest InvestLog snapshot shows $1,169.93 with -1.58% on the session and $1.10T in market capitalization; recent performance reads 1-month +7.51% and YTD +2.18%.
The latest financial table shown here is Q1 2026, with revenue of $19.80B, net income of $7.40B, and EPS of $8.26. Investors can compare that operating picture with valuation signals such as P/E 43.01 and FCF yield 1.3%.
InvestLog's latest related AI research is a Stock Price Move note titled "Eli Lilly and Company (LLY) falls 4.34% to $1,137". The latest indexable market news headline is "Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $1,280.00; recent insider activity includes Alvarez Ralph filing A-Award; recent congressional disclosure data includes Byron Donalds Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
43.01
PEG
0.45
P/B
31.49
P/S
14.31
EV/EBITDA
32.05
DCF Value
$497.85
FCF Yield
1.3%
Div Yield
0.6%
Margins & Returns
Gross Margin
83.5%
Operating Margin
45.9%
Net Margin
35.0%
ROE
101.3%
ROA
21.7%
ROIC
32.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $19.80B | $7.40B | $8.26 |
| Q4 2025 | $19.29B | $6.64B | $7.39 |
| FY 2025 | $65.18B | $20.64B | $22.95 |
| Q3 2025 | $17.60B | $5.58B | $6.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$1,271.24
Target (Median)
$1,280.00
Target Range
$1,119.00 - $1,400.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
Eli Lilly and Company (LLY) falls 4.34% to $1,137Eli Lilly and Company(LLY)下跌 4.34%,报 $1,137
Eli Lilly and Company (LLY) traded 4.34% lower at $1,137 as of 2026-10-08T14:26:58+00:00. Reported session volume was 698,508 shares, or approximately $794M in turnover.Eli Lilly and Company(LLY)截至 2026-10-08T14:26:58+00:00 下跌 4.34%,报 $1,137。当日成交量为 698,508 股,成交额估算约 $794M。
Eli Lilly and Company (LLY) rises 4.04% to $1,204Eli Lilly and Company(LLY)上涨 4.04%,报 $1,204
Eli Lilly and Company (LLY) traded 4.04% higher at $1,204 as of 2026-10-07T15:35:39+00:00. Reported session volume was 826,135 shares, or approximately $995M in turnover.Eli Lilly and Company(LLY)截至 2026-10-07T15:35:39+00:00 上涨 4.04%,报 $1,204。当日成交量为 826,135 股,成交额估算约 $995M。
LLY regulated product launch: Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICsEli Lilly and Company(LLY)正式推出获批药品或治疗产品
LLY regulated product launch: Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs.Eli Lilly and Company(LLY)正式推出获批药品或治疗产品。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.52
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.